This study is testing a new combination of two oral medications, ziftomenib and quizartinib, for adults with acute myeloid leukemia (AML) that has come back or hasn't responded to previous treatments. The goal is to find the safest and most effective dose of these drugs when given together. Researchers are also looking at how well this combination works in people with specific genetic changes in their AML (NPM1mt, KMT2Ar, or NUP98r). You may be able to join if you are 18 or older, have one of these genetic changes, and meet other health criteria. The main focus of this study is to understand the safety and any side effects you might experience.

Study design

This is an interventional study with a planned enrollment of 44 participants. It aims to determine the best dose of ziftomenib in combination with quizartinib.

What's involved

Participants will receive ziftomenib and quizartinib in tablet form. The study will assess safety and adverse events through study completion, which is an average of 1 year.

Compensation

Not stated in the trial record.

Follow-up

Safety and adverse events will be measured through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.